DIP2B (Q9P265) variants and mutations
DIP2B (also known as Q9P265) is a human protein-coding gene encoding a disco-interacting protein 2 homolog B protein. It participates in neuronal and developmental regulation, with proposed roles in DNA methylation and lipid metabolism, although its molecular functions remain incompletely defined. CGG-repeat expansion and silencing at the locus cause fragile site FRA12A-associated intellectual disability. This analysis covers 1,644 DIP2B variants and mutations. Of these, 95% have computational variant effect predictions. Disease context includes Abnormality of the skeletal system, intellectual disability, FRA12A type, and hypertensive disorder. Example DIP2B variants include M1?, A2S, and A2T.
Variant analysis overview
- Gene: DIP2B
- Protein: Q9P265
- UniProt accession: Q9P265
- Organism: Homo sapiens
- Variants analyzed: 1644
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 1,438 unspecified-consequence records; 114 missense variants; 70 synonymous variants; 10 stop-gained variants; 6 frameshift variants; 2 in-frame deletions; 4 splice-region variants
- Prediction scores: 1,569 variants have prediction scores (95% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: Abnormality of the skeletal system, intellectual disability, FRA12A type, hypertensive disorder, atrial fibrillation, coronary artery disorder, bipolar disorder, alcohol drinking, urolithiasis, atrial septal defect, venous thromboembolism, Varicose veins, ischemic stroke.
Protein structure and variant hotspots
- Protein features: 1 domains; 13 post-translational modification sites.
- Structural context: 277 variants have structural context.
- PTM context: 15 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable DIP2B variants
Examples include M1?, A2S, A2T, A2G, A2E, A2V, A2A, E3K. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1?, NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- A2S (p.Ala2Ser), gnomAD 12-50505144-G-T, REVEL 0.07, MetaLR 0.04
- A2T (p.Ala2Thr), gnomAD 12-50505144-G-A, REVEL 0.07, MetaLR 0.05
- A2G (p.Ala2Gly), gnomAD 12-50505145-C-G, REVEL 0.07, MetaLR 0.05
- A2E (p.Ala2Glu), gnomAD 12-50505145-C-A, REVEL 0.09, MetaLR 0.05
- A2V (p.Ala2Val), gnomAD 12-50505145-C-T, REVEL 0.09, MetaLR 0.05
- A2A (p.Ala2Ala), gnomAD 12-50505146-G-T, CADD 15.20
- E3K (p.Glu3Lys), gnomAD 12-50505147-G-A, REVEL 0.21, MetaLR 0.05
- E3* (p.Glu3Ter), gnomAD 12-50505147-G-T, CADD 37.00
- E3V (p.Glu3Val), gnomAD 12-50505148-A-T, REVEL 0.15, MetaLR 0.05
- E3G (p.Glu3Gly), gnomAD 12-50505148-A-G, REVEL 0.13, MetaLR 0.05
- E3E (p.Glu3Glu), rs1209473808, gnomAD 12-50505149-A-G, CADD 14.90
- R4L (p.Arg4Leu), TOPMed rs888393696, gnomAD rs888393696, REVEL 0.20, MetaLR 0.06, Uncertain significance
- R4P (p.Arg4Pro), rs888393696, ClinGen CA236782368, ClinVar RCV004258728, TOPMed rs888393696, REVEL 0.23, MetaLR 0.08, Uncertain significance, not specified
- R4* (p.Arg4Ter), gnomAD 12-50505150-C-T, CADD 36.00
- R4Q (p.Arg4Gln), gnomAD 12-50505151-G-A, REVEL 0.12, MetaLR 0.06
- R4R (p.Arg4Arg), rs752774862, gnomAD 12-50505152-A-T, CADD 15.70
- G5C (p.Gly5Cys), gnomAD 12-50505153-G-T, REVEL 0.16, MetaLR 0.08
- G5R (p.Gly5Arg), gnomAD 12-50505153-G-C, REVEL 0.18, MetaLR 0.06
- G5V (p.Gly5Val), gnomAD 12-50505154-G-T, REVEL 0.18, MetaLR 0.05
- G5G (p.Gly5Gly), gnomAD 12-50505155-C-T, CADD 15.70
- L6R (p.Leu6Arg), TOPMed rs1006771450, gnomAD rs1006771450, REVEL 0.23, MetaLR 0.03
- L6L (p.Leu6Leu), rs1302249961, gnomAD 12-50505156-C-T, CADD 14.30
- L6Q (p.Leu6Gln), gnomAD 12-50505157-T-A, REVEL 0.25, MetaLR 0.03
- L6P (p.Leu6Pro), gnomAD 12-50505157-T-C, REVEL 0.26, MetaLR 0.03
- E7G (p.Glu7Gly), gnomAD rs1218513753, REVEL 0.17, MetaLR 0.03
- E7Q (p.Glu7Gln), 1000Genomes rs1016840774, TOPMed rs1016840774, gnomAD rs1016840774, REVEL 0.09, MetaLR 0.02
- E7* (p.Glu7Ter), gnomAD 12-50505159-G-T, CADD 37.00
- E7V (p.Glu7Val), gnomAD 12-50505160-A-T, REVEL 0.21, MetaLR 0.03
- E7D (p.Glu7Asp), gnomAD 12-50505161-G-T, REVEL 0.03, MetaLR 0.02
- E7E (p.Glu7Glu), gnomAD 12-50505161-G-A, CADD 14.10
- P8A (p.Pro8Ala), 1000Genomes rs527464151, TOPMed rs527464151, gnomAD rs527464151, REVEL 0.10, MetaLR 0.02, Uncertain significance, not specified
- P8R (p.Pro8Arg), TOPMed rs1293715149, gnomAD rs1293715149, REVEL 0.15, MetaLR 0.02
- P8T (p.Pro8Thr), 1000Genomes rs527464151, TOPMed rs527464151, gnomAD rs527464151, REVEL 0.09, MetaLR 0.02
- P8S (p.Pro8Ser), gnomAD 12-50505162-C-T, REVEL 0.09, MetaLR 0.02
- P8L (p.Pro8Leu), gnomAD 12-50505163-C-T, REVEL 0.11, MetaLR 0.02
- P8P (p.Pro8Pro), rs1016290231, gnomAD 12-50505164-G-T, CADD 13.10
- S9L (p.Ser9Leu), rs1466454746, ClinGen CA384818980, ClinVar RCV003146091, TOPMed rs1466454746, REVEL 0.09, MetaLR 0.04, Uncertain significance, Intellectual disability, FRA12A type
- S9P (p.Ser9Pro), Ensembl rs1957955151, MetaLR 0.03, MetaSVM -1.00
- S9* (p.Ser9Ter), gnomAD 12-50505166-C-A, CADD 36.00
- S9S (p.Ser9Ser), gnomAD 12-50505167-G-A, CADD 14.90
- P10S (p.Pro10Ser), TOPMed rs895107881, gnomAD rs895107881, REVEL 0.03, MetaLR 0.03
- P10A (p.Pro10Ala), gnomAD 12-50505168-C-G, REVEL 0.03, MetaLR 0.03
- P10L (p.Pro10Leu), gnomAD 12-50505169-C-T, REVEL 0.05, MetaLR 0.03
- P10P (p.Pro10Pro), gnomAD 12-50505170-G-C, CADD 14.50
- A11T (p.Ala11Thr), gnomAD 12-50505171-G-A, REVEL 0.03, MetaLR 0.03
- A11S (p.Ala11Ser), gnomAD 12-50505171-G-T, REVEL 0.03, MetaLR 0.03
- A11D (p.Ala11Asp), gnomAD 12-50505172-C-A, REVEL 0.14, MetaLR 0.04
- A11A (p.Ala11Ala), rs1012751932, gnomAD 12-50505173-C-T, CADD 12.90
- A12E (p.Ala12Glu), 1000Genomes rs201679381, REVEL 0.25, MetaLR 0.02
- A12T (p.Ala12Thr), gnomAD rs1477084146, REVEL 0.13, MetaLR 0.03
- A12V (p.Ala12Val), 1000Genomes rs201679381, REVEL 0.12, MetaLR 0.02
- A12S (p.Ala12Ser), gnomAD 12-50505174-G-T, REVEL 0.07, MetaLR 0.02
- A12A (p.Ala12Ala), gnomAD 12-50505176-G-T, CADD 14.80
- V13A (p.Val13Ala), 1000Genomes rs547240228, TOPMed rs547240228
- V13E (p.Val13Glu), 1000Genomes rs547240228, TOPMed rs547240228
- V13G (p.Val13Gly), 1000Genomes rs547240228, TOPMed rs547240228, MetaLR 0.04, MetaSVM -1.06
- V13L (p.Val13Leu), gnomAD 12-50505177-G-T, REVEL 0.07, MetaLR 0.03
- V13M (p.Val13Met), gnomAD 12-50505177-G-A, REVEL 0.11, MetaLR 0.04
- V13V (p.Val13Val), gnomAD 12-50505179-G-A, CADD 14.80
- A14E (p.Ala14Glu), TOPMed rs1381140625, gnomAD rs1381140625, REVEL 0.26, MetaLR 0.08, Uncertain significance
- A14T (p.Ala14Thr), TOPMed rs1193179828, gnomAD rs1193179828, REVEL 0.16, MetaLR 0.07
- A14V (p.Ala14Val), rs1381140625, ClinGen CA384819006, ClinVar RCV004125573, TOPMed rs1381140625, REVEL 0.14, MetaLR 0.08, Uncertain significance, not specified
- A14R (p.Ala14Arg), gnomAD 12-50505178-TG-T, CADD 28.00
- A14G (p.Ala14Gly), gnomAD 12-50505181-C-G, REVEL 0.20, MetaLR 0.09
- A14A (p.Ala14Ala), rs1441852888, gnomAD 12-50505182-G-C, CADD 14.40
- A15T (p.Ala15Thr), gnomAD 12-50505183-G-A, REVEL 0.07, MetaLR 0.13
- A15S (p.Ala15Ser), gnomAD 12-50505183-G-T, REVEL 0.04, MetaLR 0.10
- A15V (p.Ala15Val), gnomAD 12-50505184-C-T, REVEL 0.08, MetaLR 0.11
- A15A (p.Ala15Ala), gnomAD 12-50505185-G-A, CADD 15.70
- L16P (p.Leu16Pro), gnomAD rs1157202199, MetaLR 0.46, MetaSVM -0.21
- L16M (p.Leu16Met), gnomAD 12-50505186-C-A, REVEL 0.39, MetaLR 0.43
- L16L (p.Leu16Leu), rs972620231, gnomAD 12-50505186-C-T, CADD 14.30
- P17L (p.Pro17Leu), rs1384765015, ClinGen CA384819023, ClinVar RCV004352181, TOPMed rs1384765015, REVEL 0.64, MetaLR 0.82, Uncertain significance, not specified
- P17S (p.Pro17Ser), gnomAD 12-50505189-C-T, REVEL 0.60, MetaLR 0.78
- P17T (p.Pro17Thr), gnomAD 12-50505189-C-A, REVEL 0.64, MetaLR 0.82
- P17Q (p.Pro17Gln), gnomAD 12-50505190-C-A, REVEL 0.57, MetaLR 0.82
- P17P (p.Pro17Pro), rs758435927, gnomAD 12-50505191-G-A, CADD 13.40
- P18S (p.Pro18Ser), gnomAD rs1326109803, REVEL 0.04, MetaLR 0.05, Uncertain significance, not specified
- P18L (p.Pro18Leu), gnomAD 12-50505193-C-T, REVEL 0.01, MetaLR 0.03
- P18H (p.Pro18His), gnomAD 12-50505193-C-A, REVEL 0.07, MetaLR 0.07
- E19Q (p.Glu19Gln), Ensembl rs1957955528, REVEL 0.28, MetaLR 0.20
- E19* (p.Glu19Ter), gnomAD 12-50505195-G-T, CADD 37.00
- E19K (p.Glu19Lys), gnomAD 12-50505195-G-A, REVEL 0.28, MetaLR 0.20
- E19G (p.Glu19Gly), gnomAD 12-50505196-A-G, REVEL 0.30, MetaLR 0.24
- E19E (p.Glu19Glu), gnomAD 12-50505197-A-G, CADD 16.30
- V20L (p.Val20Leu), gnomAD 12-50505198-G-T, REVEL 0.18, MetaLR 0.24
- V20V (p.Val20Val), gnomAD 12-50505200-G-T, CADD 14.70
- R21W (p.Arg21Trp), TOPMed rs1957955547, gnomAD rs1957955547, REVEL 0.33, MetaLR 0.30
- R21R (p.Arg21Arg), rs1957955547, gnomAD 12-50505201-C-A, CADD 15.90
- R21L (p.Arg21Leu), gnomAD 12-50505202-G-T, REVEL 0.32, MetaLR 0.31
- A22V (p.Ala22Val), gnomAD rs1351054893, REVEL 0.06, MetaLR 0.08
- A22T (p.Ala22Thr), gnomAD 12-50505204-G-A, REVEL 0.07, MetaLR 0.07
- A22S (p.Ala22Ser), gnomAD 12-50505204-G-T, REVEL 0.05, MetaLR 0.08
- A22E (p.Ala22Glu), gnomAD 12-50505205-C-A, REVEL 0.27, MetaLR 0.04
- A22A (p.Ala22Ala), gnomAD 12-50505206-G-T, CADD 14.80
- Q23R (p.Gln23Arg), gnomAD rs1438060161, REVEL 0.12, MetaLR 0.05
- Q23* (p.Gln23Ter), gnomAD 12-50505207-C-T, CADD 37.00
- Q23P (p.Gln23Pro), gnomAD 12-50505208-A-C, REVEL 0.19, MetaLR 0.16
- Q23H (p.Gln23His), gnomAD 12-50505209-G-T, REVEL 0.18, MetaLR 0.12
- Q23Q (p.Gln23Gln), rs1957955609, gnomAD 12-50505209-G-A, CADD 14.00
- L24L (p.Leu24Leu), gnomAD 12-50505210-C-T, CADD 14.80
- L24P (p.Leu24Pro), gnomAD 12-50505211-T-C, REVEL 0.65, MetaLR 0.50
- A25T (p.Ala25Thr), gnomAD 12-50505213-G-A, REVEL 0.23, MetaLR 0.23
- A25S (p.Ala25Ser), gnomAD 12-50505213-G-T, REVEL 0.16, MetaLR 0.16
- A25V (p.Ala25Val), gnomAD 12-50505214-C-T, REVEL 0.26, MetaLR 0.25
- A25E (p.Ala25Glu), gnomAD 12-50505214-C-A, REVEL 0.30, MetaLR 0.20
- A25A (p.Ala25Ala), gnomAD 12-50505215-G-T, CADD 14.30
- E26K (p.Glu26Lys), gnomAD 12-50505216-G-A, REVEL 0.28, MetaLR 0.20
- E26* (p.Glu26Ter), gnomAD 12-50505216-G-T, CADD 38.00
- E26G (p.Glu26Gly), gnomAD 12-50505217-A-G, REVEL 0.30, MetaLR 0.20
- E26E (p.Glu26Glu), rs764592096, gnomAD 12-50505218-G-A, CADD 14.40
- E26D (p.Glu26Asp), gnomAD 12-50505218-G-T, REVEL 0.20, MetaLR 0.20
- L27V (p.Leu27Val), Ensembl rs1957955713, REVEL 0.51, MetaLR 0.55
- L27M (p.Leu27Met), gnomAD 12-50505219-C-A, REVEL 0.51, MetaLR 0.61
- L27L (p.Leu27Leu), gnomAD 12-50505219-C-T, CADD 15.20
- L27P (p.Leu27Pro), gnomAD 12-50505220-T-C, REVEL 0.76, MetaLR 0.62
- E28* (p.Glu28Ter), gnomAD rs1241932381, CADD 39.00
- E28G (p.Glu28Gly), NCI-TCGA TCGA novel, REVEL 0.21, MetaLR 0.16, Variant assessed as somatic; moderate impact.
- E28D (p.Glu28Asp), gnomAD 12-50505224-G-T, REVEL 0.07, MetaLR 0.04
- L29L (p.Leu29Leu), gnomAD 12-50505225-C-T, CADD 15.20
- p.Glu30 Leu31del, gnomAD 12-50505214-CGGAG, CADD 21.90
- E30K (p.Glu30Lys), gnomAD 12-50505228-G-A, REVEL 0.26, MetaLR 0.23
- E30* (p.Glu30Ter), gnomAD 12-50505228-G-T, CADD 38.00
- E30G (p.Glu30Gly), gnomAD 12-50505229-A-G, REVEL 0.24, MetaLR 0.19
- E30E (p.Glu30Glu), gnomAD 12-50505230-G-A, CADD 14.40
- E30D (p.Glu30Asp), gnomAD 12-50505230-G-T, REVEL 0.14, MetaLR 0.15
- L31F (p.Leu31Phe), gnomAD 12-50505231-C-T, REVEL 0.26, MetaLR 0.25
- L31L (p.Leu31Leu), gnomAD 12-50505233-C-T, CADD 14.10
- S32W (p.Ser32Trp), TOPMed rs1476416218, REVEL 0.34, MetaLR 0.24
- S32P (p.Ser32Pro), gnomAD 12-50505234-T-C, REVEL 0.26, MetaLR 0.22
- S32L (p.Ser32Leu), gnomAD 12-50505235-C-T, REVEL 0.23, MetaLR 0.21
- S32S (p.Ser32Ser), gnomAD 12-50505236-G-T, CADD 10.60
- E33* (p.Glu33Ter), gnomAD 12-50505237-G-T, CADD 40.00
- E33D (p.Glu33Asp), gnomAD 12-50505239-G-T, REVEL 0.20, MetaLR 0.16
- E33E (p.Glu33Glu), gnomAD 12-50505239-G-A, CADD 18.20
- G34R (p.Gly34Arg), Ensembl rs1025869852, REVEL 0.49, MetaLR 0.37
- G34E (p.Gly34Glu), gnomAD 12-50625976-G-A, REVEL 0.41, MetaLR 0.38
- G34G (p.Gly34Gly), gnomAD 12-50625977-G-A, CADD 16.50
- D35G (p.Asp35Gly), rs1443278274, NCI-TCGA Cosmic COSV9999, 1000Genomes rs1443278274, gnomAD rs1443278274, REVEL 0.40, MetaLR 0.32, Variant assessed as somatic; moderate impact.
- D35N (p.Asp35Asn), TOPMed rs771246405, gnomAD rs771246405, REVEL 0.36, MetaLR 0.27
- D35Y (p.Asp35Tyr), TOPMed rs771246405, gnomAD rs771246405, REVEL 0.47, MetaLR 0.34
- D35D (p.Asp35Asp), gnomAD 12-50625980-C-T, CADD 10.00
- I36V (p.Ile36Val), gnomAD 12-50625981-A-G, REVEL 0.28, MetaLR 0.32
- T37A (p.Thr37Ala), NCI-TCGA TCGA novel, MetaLR 0.47, MetaSVM -0.06, Variant assessed as somatic; moderate impact.
- T37I (p.Thr37Ile), gnomAD rs1937926423, REVEL 0.66, MetaLR 0.52
- T37T (p.Thr37Thr), gnomAD 12-50625986-C-T, CADD 9.55
- Q38R (p.Gln38Arg), gnomAD 12-50625988-A-G, REVEL 0.31, MetaLR 0.27
- Q38L (p.Gln38Leu), gnomAD 12-50625988-A-T, REVEL 0.42, MetaLR 0.28
- Q38Q (p.Gln38Gln), rs1362020518, gnomAD 12-50625989-G-A, CADD 9.89
- K39K (p.Lys39Lys), rs773119511, gnomAD 12-50625992-G-A, CADD 6.40
- K39N (p.Lys39Asn), gnomAD 12-50625992-G-C, REVEL 0.50, MetaLR 0.40
- G40G (p.Gly40Gly), rs1433812173, gnomAD 12-50625995-C-T, CADD 10.90
- Y41C (p.Tyr41Cys), gnomAD 12-50625997-A-G, REVEL 0.62, MetaLR 0.32
- Y41Y (p.Tyr41Tyr), rs760566973, gnomAD 12-50625998-T-C, CADD 8.63
- R45S (p.Arg45Ser), ESP rs370478703, ExAC rs370478703, TOPMed rs370478703, gnomAD rs370478703, REVEL 0.34, MetaLR 0.30
- R45K (p.Arg45Lys), gnomAD 12-50626009-G-A, REVEL 0.21, MetaLR 0.10
- R45R (p.Arg45Arg), rs370478703, gnomAD 12-50626010-G-A, CADD 8.95
- S46F (p.Ser46Phe), TOPMed rs1937926749, REVEL 0.14, MetaLR 0.15
- S46P (p.Ser46Pro), NCI-TCGA TCGA novel, MetaLR 0.13, MetaSVM -0.91, Variant assessed as somatic; moderate impact.
- S46Y (p.Ser46Tyr), gnomAD 12-50626012-C-A, REVEL 0.13, MetaLR 0.19
- S46S (p.Ser46Ser), rs187283930, gnomAD 12-50626013-C-T, CADD 9.92
- K47E (p.Lys47Glu), ExAC rs764064387, gnomAD rs764064387, REVEL 0.22, MetaLR 0.26
- K47R (p.Lys47Arg), gnomAD rs1937926893, REVEL 0.22, MetaLR 0.19
- K47K (p.Lys47Lys), rs751724137, gnomAD 12-50626016-A-G, CADD 9.93
- L48L (p.Leu48Leu), rs146296554, gnomAD 12-50626019-C-T, CADD 5.81
- L49L (p.Leu49Leu), rs147599326, gnomAD 12-50626022-A-G, CADD 8.53
- S50Y (p.Ser50Tyr), rs750739469, ExAC rs750739469, TOPMed rs750739469, gnomAD rs750739469, REVEL 0.19, MetaLR 0.08, Variant assessed as somatic; moderate impact.
- P51T (p.Pro51Thr), gnomAD 12-50626026-C-A, REVEL 0.14, MetaLR 0.19
- Y52H (p.Tyr52His), gnomAD rs1937927227, REVEL 0.33, MetaLR 0.29
- Y52Y (p.Tyr52Tyr), rs1937927273, gnomAD 12-50626031-C-T, CADD 10.10
- S53G (p.Ser53Gly), TOPMed rs1424546960, MetaLR 0.05, MetaSVM -1.05
- P54L (p.Pro54Leu), rs754872797, ClinGen CA6564161, ClinVar RCV004373774, ExAC rs754872797, REVEL 0.12, MetaLR 0.12, Uncertain significance, not specified
- P54R (p.Pro54Arg), gnomAD 12-50626036-C-G, REVEL 0.20, MetaLR 0.19
- P54P (p.Pro54Pro), rs779617308, gnomAD 12-50626037-G-T, CADD 4.69
- Q55* (p.Gln55Ter), Ensembl rs1937927514, CADD 37.00
- Q55R (p.Gln55Arg), Ensembl rs943156819, MetaLR 0.06, MetaSVM -1.10
- Q55Q (p.Gln55Gln), rs1414015632, gnomAD 12-50626040-G-A, CADD 9.23
- T56T (p.Thr56Thr), rs748906798, gnomAD 12-50626043-A-C, CADD 8.58
- Q57=, NCI-TCGA TCGA novel, Variant assessed as somatic; low impact.
Public DIP2B analysis runs
- DIP2B analysis run — DIP2B (1,644 variants) — completed 2026-08-19